Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fondaparinux Sodium

FDA-approved product (solution, subcutaneous), marketed as Arixtra, Fondaparinux Sodium.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Fondaparinux Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Deep vein thrombosis
  • Intermediate coronary syndrome
  • Myocardial infarction
  • Pulmonary embolism
  • Recurrent thrombophlebitis
  • Venous thrombosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antithrombotic agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae42.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fondaparinux Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fondaparinux Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis

    NCT07299695 · start 2026-01-25

    Registered record
    Registry ID
    NCT07299695
    Conditions
    Idiopathic Pulmonary Fibrosis; Acute Exacerbation of Idiopathic Pulmonary Fibrosis
    Interventions
    Intravenous immunoglobulin (IVIG); Usual treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-01-25
    Completion
    2028-12
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Pulmonary Fibrosis; Acute Exacerbation of Idiopathic Pulmonary Fibrosis
    InterventionIntravenous immunoglobulin (IVIG); Usual treatment
    PhasePhase 3
    Registry statusRecruiting

  • Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial Infarction

    NCT06710184 · start 2025-05-01

    Registered record
    Registry ID
    NCT06710184
    Conditions
    NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI); Acute Myocardial Infarction (AMI)
    Interventions
    Aspirin; Fondaparinux Sodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-05-01
    Completion
    2029-07-01
    Enrolment
    5,076

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI); Acute Myocardial Infarction (AMI)
    InterventionAspirin; Fondaparinux Sodium
    PhasePhase 4
    Registry statusRecruiting

  • Thromboprophylaxis in Lower Limb Immobilisation

    NCT06370273 · start 2024-11-12

    Registered record
    Registry ID
    NCT06370273
    Conditions
    Thrombosis; Injury Leg
    Interventions
    Rivaroxaban; Apixaban; Enoxaparin Injectable Solution; Tinzaparin Injectable Solution; Dalteparin Injectable Solution; Fondaparinux Injectable Product
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-11-12
    Completion
    2028-08-31
    Enrolment
    10,044

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThrombosis; Injury Leg
    InterventionRivaroxaban; Apixaban; Enoxaparin Injectable Solution; Tinzaparin Injectable Solution +2 more
    PhasePhase 3
    Registry statusRecruiting

  • Endovenous Laser Ablation in Acute Thrombophlebitis of the Varicose Great Saphenous Vein

    NCT05001776 · start 2021-08-16

    Registered record
    Registry ID
    NCT05001776
    Conditions
    Superficial Vein Thrombosis; Endovenous Laser Ablation
    Interventions
    Endovenous laser ablation; Fondaparinux Sodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-08-16
    Completion
    2023-12-01
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSuperficial Vein Thrombosis; Endovenous Laser Ablation
    InterventionEndovenous laser ablation; Fondaparinux Sodium
    PhasePhase 4
    Registry statusCompleted

  • Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels

    NCT04539301 · start 2021-04-01

    Registered record
    Registry ID
    NCT04539301
    Conditions
    Anticoagulation; Venous Thromboembolism; Atrial Fibrillation
    Interventions
    Estimated anticoagulant level (conversion factor x anti-Xa activity)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-04-01
    Completion
    2024-05-01
    Enrolment
    2,100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnticoagulation; Venous Thromboembolism; Atrial Fibrillation
    InterventionEstimated anticoagulant level (conversion factor x anti-Xa activity)
    PhaseNot recorded
    Registry statusUnknown

  • Impact of Continuous Veno-venous Hemodiafiltration on Efficacy of Administration of Prophylactic Doses of Enoxaparin or Fondaparinux in Critically Ill Patients.

    NCT04671160 · start 2021-01-04

    Registered record
    Registry ID
    NCT04671160
    Conditions
    Assessment of Activity of Anti-Xa Factor in Patients Treated With Continuous Veno-venous Hemodiafiltration Receiving Anticoagulant Prophylaxis
    Interventions
    Assessment the activity of anti-Xa factor.
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-01-04
    Completion
    2022-09-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAssessment of Activity of Anti-Xa Factor in Patients Treated With Continuous Veno-venous Hemodiafiltration Receiving Anticoagulant Prophylaxis
    InterventionAssessment the activity of anti-Xa factor.
    PhaseNot recorded
    Registry statusUnknown

  • A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic

    NCT04444700 · start 2020-07-04

    Registered record
    Registry ID
    NCT04444700
    Conditions
    COVID; Coronavirus Infection; Severe Acute Respiratory Syndrome; Thromboembolism, Venous; Anticoagulants and Bleeding Disorders
    Interventions
    Therapeutic anticoagulation
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-07-04
    Completion
    2021-10-14
    Enrolment
    465

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID; Coronavirus Infection; Severe Acute Respiratory Syndrome; Thromboembolism, Venous +1 more
    InterventionTherapeutic anticoagulation
    PhasePhase 3
    Registry statusCompleted

  • Safety of Fondaparinux as Post Partum Thromboprophylaxis

    NCT04447378 · start 2017-09-01

    Registered record
    Registry ID
    NCT04447378
    Conditions
    Thromboembolism in the Puerperium
    Interventions
    Fondaparinux 2.5Mg/0.5Ml Inj Syr
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-09-01
    Completion
    2018-06-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThromboembolism in the Puerperium
    InterventionFondaparinux 2.5Mg/0.5Ml Inj Syr
    PhasePhase 4
    Registry statusCompleted

  • Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

    NCT02744092 · start 2016-12-13

    Registered record
    Registry ID
    NCT02744092
    Conditions
    Cancer; Venous Thromboembolism; Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE); Blood Clot
    Interventions
    Rivaroxaban; Apixaban; Edoxaban; Dabigatran; Warfarin; Dalteparin; Enoxaparin; Fondaparinux
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-12-13
    Completion
    2021-02-22
    Enrolment
    811

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer; Venous Thromboembolism; Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE) +1 more
    InterventionRivaroxaban; Apixaban; Edoxaban; Dabigatran +4 more
    PhaseNot applicable
    Registry statusCompleted

  • EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

    NCT02234843 · start 2014-11-13

    Registered record
    Registry ID
    NCT02234843
    Conditions
    Venous Thromboembolism
    Interventions
    Rivaroxaban (Xarelto, BAY59-7939); Rivaroxaban (Xarelto, BAY59-7939); Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-11-13
    Completion
    2019-01-30
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thromboembolism
    InterventionRivaroxaban (Xarelto, BAY59-7939); Rivaroxaban (Xarelto, BAY59-7939); Standard of Care
    PhasePhase 3
    Registry statusCompleted

  • Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy

    NCT02210819 · start 2014-06-27

    Registered record
    Registry ID
    NCT02210819
    Conditions
    Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE)
    Interventions
    Rivaroxaban (Xarelto, BAY59-7939); Recommended VTE pharmacological treatments according to international guidelines
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-06-27
    Completion
    2017-01-20
    Enrolment
    1,987

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDeep Vein Thrombosis (DVT); Pulmonary Embolism (PE)
    InterventionRivaroxaban (Xarelto, BAY59-7939); Recommended VTE pharmacological treatments according to international guidelines
    PhaseNot recorded
    Registry statusCompleted

  • Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)

    NCT01895777 · start 2013-09-25

    Registered record
    Registry ID
    NCT01895777
    Conditions
    Venous Thromboembolism
    Interventions
    dabigatran etexilate; standard of care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-09-25
    Completion
    2019-11-14
    Enrolment
    267

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thromboembolism
    Interventiondabigatran etexilate; standard of care
    PhasePhase 3
    Registry statusCompleted

  • Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy

    NCT01619007 · start 2012-06

    Registered record
    Registry ID
    NCT01619007
    Conditions
    Deep Vein Thrombosis; Venous Thrombosis
    Interventions
    Rivaroxaban (Xarelto, BAY59-7939); Standard of care
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-06
    Completion
    2015-07
    Enrolment
    5,145

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDeep Vein Thrombosis; Venous Thrombosis
    InterventionRivaroxaban (Xarelto, BAY59-7939); Standard of care
    PhaseNot recorded
    Registry statusCompleted

  • Non-culprit Vessels for ST-Segment Elevation Myocardial Infarction

    NCT02154919 · start 2011-04

    Registered record
    Registry ID
    NCT02154919
    Conditions
    Conservative Pharmacotherapy; Staged Percutaneous Coronary Intervention; Non-culprit Vessels; ST-Segment Elevation Myocardial Infarction
    Interventions
    Percutaneous coronary intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-04
    Completion
    Not recorded
    Enrolment
    306

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConservative Pharmacotherapy; Staged Percutaneous Coronary Intervention; Non-culprit Vessels; ST-Segment Elevation Myocardial Infarction
    InterventionPercutaneous coronary intervention
    PhaseNot recorded
    Registry statusCompleted

  • Determination of Residual Anticoagulatory Effects of Fondaparinux

    NCT01101256 · start 2010-04

    Registered record
    Registry ID
    NCT01101256
    Conditions
    Anticoagulant Prophylaxis/Therapy
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2010-04
    Completion
    2010-10
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnticoagulant Prophylaxis/Therapy
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown